In preclinical tumour models, PIM kinase inhibitors also have the ability to sensitise cancer cells to radiotherapy and chemotherapy.23,24 For example, in a mouse xenograft model of non-small-cell lung cancer, PIM inhibition sensitised cancer cells to radiation23 and PIM antagonism in prostate cancer cells sensitised the cells to the chemotherapeutic gemcitabine.24 Thus, PIM kinase inhibitors may be important in contexts where PIM kinases are acting with other therapeutic targets to drive oncogenic progression. Here, PIM1 is linked to Familial prostate cancer.